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Introduction: We conducted a prospective observational study in cardiac arrest survivors treated with mild induced
hypothermia, evaluating different platelet function tests at hypo- and normothermia. We also investigated the
relation between gastric emptying and vasodilator stimulated phosphoprotein (VASP).
Methods: Comatose survivors of out of hospital cardiac arrest were included and divided into two groups,
depending on whether dual platelet inhibition with peroral ticagrelor and aspirin was given or not. The first blood
samples (T1) were collected 12–24 hours after reaching target temperature (33°C) and were compared to blood
samples collected 12–28 hours after reaching normothermia (37°C) (T2) within each group. All samples were
analysed by Sonoclot viscoelasticity, flow cytometry based VASP and with multiple electrode aggregometry,
Multiplate®; adenosine diphosphate (ADP), collagen (COL), thrombin receptor agonist peptide (TRAP) and
arachidonic acid (ASPI). Sonoclot and Multiplate® instruments were set on in vivo temperatures. Gastric secretion
from the nasogastric tube was measured to assess absorption of per orally administered antiplatelet drugs.
Differences between T1 and T2 within each group were calculated using Wilcoxon matched pairs signed test.
Significance levels were set at P <0.01.
Results: In total, 23 patients were included. In patients with dual platelet inhibition (n =14) Multiplate®-analyses
showed no changes in ADP stimulated platelets. COL, TRAP and ASPI aggregations were higher at T2 compared to
T1. Sonoclot-analyses showed that activated clotting time (ACT) was unchanged but both clot rate (CR) and platelet
function (PF) were higher at T2 compared to T1. VASP decreased from 53 ± 28(T1) to 24 ± 22(T2), (P <0.001). The
average volume of gastric secretion aspirated before T1 correlated well with VASP (T1), r =0.81 (P <0.001). In patients
with no platelet inhibition, (n =9) similar changes between T1 and T2 were seen as in patients with dual platelet
inhibition while VASP was unchanged.
Conclusions: We have demonstrated increased platelet aggregation and strengthened clot formation over time in
out of hospital cardiac arrest patients treated with hypothermia. In patients on oral dual platelet inhibition, the
effect of ticagrelor was delayed, probably due to slow gastric emptying.* Correspondence: thomas.kander@med.lu.se
Department of Intensive and Perioperative Care, Skåne University Hospital
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Mild induced hypothermia (MIH) is indicated for coma-
tose survivors of out-of-hospital cardiac arrest (OHCA) to
improve neurological outcome [1-3]. However, a recent
multicenter study - the target temperature management
(TTM) trial [4] in OHCA patients found that a targeted
temperature of 33°C did not confer a benefit as compared
with a targeted temperature of 36°C and has in some sense
challenged current guidelines.
In trauma, hypothermia increases bleeding and worsens
outcome [5,6]. Therefore MIH is considered contraindi-
cated in cardiac arrest patients with bleeding and espe-
cially intracerebral bleeding [3] and computer tomography
(CT) of the brain is often performed prior to MIH.
Conventional wisdom holds that hypothermia reduces
coagulation, platelet function and impairs primary and
secondary haemostasis. Whether this is true also during
MIH is still debated [7]. A few animal studies support
weakened markers of haemostasis during hypothermia
[8-12] while others do not [13-15]. Several reports of stud-
ies performed using blood from healthy volunteers, which
was incubated at different temperatures, have been pub-
lished with contradictory results. Some studies show that
hypothermia decreases haemostasis [16-21], while others
show the opposite [22-26]. Studies including patients
treated with MIH after OHCA are more infrequent. In
two such studies [27,28] thromboelastography analyses
were performed, both studies indicating decreased coagu-
lation with prolonged clot initiation during hypothermia.
Cardiac arrest patients often undergo emergency coron-
ary interventions with stenting, and receive dual antiplate-
let therapy, including aspirin and a P2Y12 antagonist. The
effect of platelet inhibition with the P2Y12-antagonist
pro-drug clopidogrel may vary secondary to differences
in intestinal absorption, variations in liver cytochrome ac-
tivities, drug interactions, and platelet receptor polymor-
phisms [29].
Viscoelastic tests such as thromboelastography or
Sonoclot do not detect aspirin or P2Y12-antagonist ef-
fects on haemostasis [30]. With flow cytometry-based
vasodilator-stimulated phosphorylated phosphoprotein
(VASP) analysis, the effect of P2Y12-antagonists can be
detected and has been shown to be decreased when clo-
pidogrel is given during MIH [31,32]. To our knowledge
there are presently no studies analysing VASP in patients
receiving the more potent P2Y12-antagonist, ticagrelor,
together with aspirin in the OHCA treatment setting.
Additionally, cardiac arrest patients develop a systemic
inflammatory response syndrome (SIRS) analogous to
the changes seen in sepsis, which may be both pro- and
antihaemostatic [33-36].
Multiple electrode aggregometry (Multiplate®) is a rela-
tively new tool used to assess adequate patient response
to platelet inhibitors [37] and also to evaluate plateletaggregability in sepsis [33,35,36]. The viscoelastic test,
Sonoclot has been shown to be superior to thromboelas-
tographic methods for detection of platelet inhibition in
hypothermic animals, using glass bead activation [11,15].
It is unknown how haemostasis measured with Multiplate®
and Sonoclot is affected after OHCA and MIH in the in-
tensive care setting and the effect of ticagrelor on the
VASP analysis is also unexplored. We conducted a pro-
spective observational study in cardiac arrest survivors
either with or without ticagrelor and aspirin treatment
and assessed haemostasis using Multiplate®, Sonoclot and
VASP. We also investigated the relationship between gas-
tric emptying and VASP.
Methods
This prospective, observational, single-centre study was
approved by the regional ethical review board in Lund
(registration numbers 411/2004, 223/2008 and 2013/284)
and included comatose survivors of OHCA of all origins
at the Department of Intensive and Perioperative Care,
Skåne University Hospital, Lund, Sweden from February
2012 to October 2013. Informed and written consent was
obtained from the next of kin and from all survivors.
Patients were eligible if they had return of spontaneous
circulation (ROSC) after non-traumatic OHCA of any ori-
gin, were comatose (Glasgow coma scale (GCS) score ≤7)
upon admission, and >18 years old. Exclusion criteria
were pregnancy, suspicion of intracranial haemorrhage,
diagnosed terminal illness, known coagulopathy, and
anticoagulant therapy (other than prophylactic dose of
low-molecular-weight heparin (LMWH)). Patients were
divided into two groups dependent on whether they re-
ceived dual platelet inhibition or not. All analyses were
performed over time within each group; no comparisons
were made between the groups.
Patients were investigated with CT of the brain to rule
out cerebral haemorrhage before inclusion. Coronary
angiography and percutaneous coronary intervention
(PCI) was performed at the discretion of the treating car-
diologist. All patients were treated in accordance with a
standardized protocol for MIH. Hypothermia was induced
with cold saline (30 ml/kg) and maintained using a cooling
device, that is, surface cooling (Arctic Sun®, Medivance®,
Louisville, CO, USA) or intravascular cooling (IcyCath®,
ZOLL, Sunnyvale, CA, USA) at the discretion of the
responsible intensivist. Patients received hypothermia
for 24 h at 33 ± 1°C and controlled rewarming at 0.5°C/h.
Patients received the following standardized procedures:
Foley catheters with incorporated temperature probes,
arterial catheters, central venous catheters, and mechan-
ical ventilation after intubation. Patients were sedated with
propofol 2 to 4 mg/kg/h and fentanyl 1 to 3 μg/kg/h.
Neuromuscular blockade was induced with rocuronium
(0.5 mg/kg bolus) if needed, to treat shivering. Enteral
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tion, New York, NY, USA) was started on arrival at the
ICU, at 10 ml/h and continued throughout the study
period. Aspiration of gastric secretions from the nasogastric
tube was performed every 4 h and enteral nutrition paused
if the aspirate exceeded 200 ml. The average aspirated
volume was registered. See Gastric secretion below, and
flowchart (Figure 1).
Anticoagulation and platelet inhibition
No patients received thrombolysis. All patients received
LMWH, enoxaparin, 40 mg subcutaneously once daily.
The clinician decided whether patients should receive
dual platelet inhibition with ticagrelor (180 mg loading
dose followed by 90 mg twice daily) and aspirin (300 mg
loading dose followed by 75 mg daily), normally depend-
ing on whether or not emergency PCI was performed.
Administration of the dual platelet inhibition was stan-
dardized; a loading dose was given 0 to 4 h before target
temperature was reached and further maintenance doses
were given every 12 (ticagrelor) or 24 (aspirin) h. In the
data analysis patients treated with dual platelet inhibition
were treated separately from patients not receiving this
treatment.
Blood sampling
Blood was drawn through an arterial catheter using a
Safedraw™ PMSET 1DT, (Argon Critical Care Systems,
Singapore) and collected in a vacutainer system (BD,
Plymouth, UK). The first sampling occasion, time-1 (T1),
was during stable hypothermia, that is, 12 to 24 h after
reaching target temperature (33°C). The second sampling
occasion (T2) was 12 to 28 h after reaching normothermia.
Blood samples were analysed at each time point by
conventional coagulation tests (activated partial throm-
boplastin time (aPTT), prothrombin time, international
normalized ratio (PT-INR), platelet count and fibrinogen)
along with Multiplate®, Sonoclot, VASP and C-reactiveFigure 1 Flowchart. Loading and daily doses of ticacrelor and aspirin at th
and aspirin. All patients received enoxaparin. T1 blood samples 12 to 24 h
reaching normothermia. OHCA, out-of-hospital cardiac arrest; MIH, mild indprotein (CRP). Blood samples for Multiplate® analysis were
collected in 3.0-ml tubes containing recombinant hirudin
(Dynabyte GmbH, Munich, Germany). Blood for VASP-
analysis was collected in a 4.5-ml tube containing 0.109 M
citrate (BD Vacutainer systems, Plymouth, UK). The Sono-
clot analysis was performed on native blood collected in a
2-ml syringe (BD, Plymouth, UK).
Conventional haematological tests: PT-INR, aPTT,
fibrinogen and platelet count analyses were performed at
the accredited hospital laboratory. PT-INR, aPTT and
fibrinogen were measured using a Sysmex 5100 analyzer
(Siemens Healthcare Diagnostics, Marburg, Germany).
The PT-INR assay was performed with the Owren PT
reagent (Siemens) calibrated using international normalized
ratio (INR) calibrators certified by the Swedish external
quality assessment organization EQUALIS AB (Uppsala,
Sweden), traceable to World Health Organisation (WHO)
RBT/90 standard. The normal value for PT-INR is <1.2.
For aPTT, actin FSL and for fibrinogen, Dade Thrombin
reagent was used (Siemens). The reference intervals have
been established locally for aPTT to 26 to 33 s and for
fibrinogen to 2 to 4 g/L.
Platelet count was measured using the Sysmex XN-10
analyzer (Siemens). The locally determined reference
range for platelet count is 165 to 387 × 109/L for adult
women and 145 to 348 × 109/L for adult men. CRP-was
measured using the Cobas 6000/8000 (Roche Diagnostics
GmbH, Mannheim, Germany) and a standard procedure;
the normal value is <3 mg/L.
VASP was analysed at 37°C using a dual colour flow
cytometer assay (PLT VASP/P2Y12, BioCytex, Marseille,
France), which is specific for P2Y12 inhibitors [38]. The
ratios between phosphorylated and non-phosphorylated
VASP were used to calculate the platelet reactivity
index (PRI), which reflects the effect of ticagrelor. Ac-
cording to previous studies, a PRI <50% is regarded
as a satisfactory effect of P2Y12 inhibitors, a PRI ≥50% is
regarded as an unsatisfactory effect of P2Y12 inhibitorse clinicians descretion (n =14). Nine patients did not receive ticagrelor
after reaching hypothermia. T2 blood samples 16 to 28 hours after
uced hypothermia.





Age, years 66 ± 8 65 ± 13
Male sex, n (%) 10 (71) 8 (89)
Simplified acute
physiology score 3
71 ± 16 75 ± 15
Estimated mortality risk, % 54 ± 27 69 ± 24
Bystander cardiopulmonary
resuscitation, n (%)
10 (71) 5 (56)
Time to return of
spontaneous circulation,
minutes
30 (5 to 45) 25 (6 to 37)
30-day mortality, n (%) 8 (58) 5 (56)
Percutaneous coronary
intervention, n (%)
12 (86) 0 (0)
Origin of cardiac arrest
Acute myocardial
infarction, n (%)
12 (86) 0 (0)
Primary arrhythmia, n (%) 2 (14) 5 (56)
Hypoxia, not hanging (%) 0 (0) 3 (33)
Hanging, n (%) 0 (0) 1 (11)
Results presented as mean± SD, n (%) or medians (range (minimum to maximum)).
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untreated patients.
Multiplate®, multiple electrode aggregometry (Roche,
Rotkreuz, Switzerland) was used to measure an agonist-
induced platelet aggregation. Hirudin-anticoagulated whole
blood was stored at room temperature before analysis
within 0.5 to 3.0 h of blood sampling. Both the samples,
taken with the patient in stable hypothermia (T1) and in
stable normothermia at (T2), were analysed with the
Multiplate® set first at 33°C in duplicate test cells and
then at 37°C in duplicate test cells. The extent of plate-
let aggregation is measured by resistance (impedance)
changes between two electrodes, and then depicted as a
graph. The area under the curve (AUC) is the best aggre-
gometry parameter of the Multiplate® test. Four test assays
were performed; ADPtest (platelet aggregation in response
to adenosine-5′-diphosphate), COLtest (platelet aggrega-
tion in response to collagen), TRAPtest (platelet aggrega-
tion in response to thrombin receptor agonist peptide)
and ASPItest (platelet aggregation in response to arachi-
donic acid).
A Sonoclot Analyzer (Sienco® Inc. Arvada, USA) with
a temperature regulated heating or cooling plate was
used to study temperature effects on native blood. Both
the samples taken with the patient in stable hypothermia
(T1) and in stable normothermia at (T2) were analysed
within 2 minutes from sampling with the Sonoclot
Analyzer set at 33°C and at 37°C. Analyses were perfor-
med in duplicate for both temperatures according to
the manufacturer’s recommendations. A glass bead test
(Sienco® gbACT + ™ Kit), which has been designed to initi-
ate coagulation in a more stable manner than previous
tests, was used. The Sonoclot measures the viscoelastic
drag-impedance that fibrin and platelets in a whole blood
sample impose upon the oscillating Sono-probe. A time-
based graph reflects the different steps in the clotting
whole blood sample, called the Sonoclot signature. The
measured parameters are with defined normal values in
parentheses are as follows: 1) ACT (activated clotting
time) (100 to 155 s) is the time taken for the first fibrin to
form, and is defined as the time it takes for the signature
to move 1% upscale from the start of the graph
(immersion response) and corresponds to aPTT and trad-
itional ACT tests; 2) clot rate (CR) (9 to 35 units/minute):
the rate of increase in the clot impedance due to fibrin
formation and polymerization (the slope of the signature
after ACT) in % of full scale per minute; 3) platelet func-
tion (PF) (>1.5 units) is the point where the squeezing out
of trapped serum in the contracting clot (sign of function-
ing platelets) exceeds the accumulation of clot bulk on the
probe and can be described as the time to peak from the
immersion response. PF performs better than previous
peak amplitude and time to peak parameters, reflecting
the gPIIb/IIIa-dependent clot retraction [40].Gastric secretion
To estimate the degree of ventricle retention, aspiration of
gastric secretions was performed every 4 h. The average as-
pirated volume during 0 to 24 h after reaching hypothermia
(for T1 samples) and during 0 to 28 h after reaching
normothermia (for the T2 samples) was registered.Statistics
Non-parametric variables (Gaussian distribution not
assumed) were summarized using the median with range
(minimum to maximum). Parametric variables were sum-
marized using mean ± SD. To reduce the risk of a Type I
error due to multiple testing the significance level was set
at a P-value <0.01. Differences between results were calcu-
lated using the two-tailed, Wilcoxon matched-pairs signed
test. Correlation coefficients were calculated using Spear-
man’s rank correlation method. Differences in categorical
data were calculated using Fisher’s exact test. All statistical
analyses were performed using GraphPad Prism 5, version
5.03; GraphPad Software, La Jolla, CA, USA.Results
Twenty-three patients were included, fourteen patients
in the group with dual platelet inhibition therapy and
nine in the group without platelet inhibition therapy.
Demographic data of all subjects are shown in Table 1.
Results from the blood analyses are shown in Table 2.
The most important findings are presented below.
Table 2 Blood analyses
With platelet inhibition (n =14 patients) With no platelet inhibition (n =9 patients)
T1 T2 P-value T1 T2 P-value
Platelets, 109/L 189 ± 59 179 ± 64 0.26 206 ± 61 191 ± 68 0.42
Prothrombin time, international normalized ratio 1.1 ± 0.1 1.2 ± 0.2 0.03 1.2 ± 0.1 1.4 ± 0.4 0.14
Activated partial thromboplastin time, s 34 ± 8 36 ± 11 0.63 34 ± 10 40 ± 17 0.08
Fibrinogen, g/L 3.2 ± 0.9 4.9 ± 1.3** 0.002 3.4 ± 1.8 5.1 ± 1.6 0.02
C-reactive protein, mg/L 52 ± 38 147 ± 72*** <0.001 73 ± 68 141 ± 28 0.02
VASP
VASP, PRI,% 53 ± 28 24 ± 22*** <0.001 83(75 to 85) 76(50 to 84) 0.38
Samples with adequate effect (PRI <50%), n (%) 7 (50) 12 (86) 0.10 1 (11) 1 (11)
Samples below normal value (PRI <70%), n (%) 9 (64) 13 (93) 0.16 1 (11) 1 (11)
Multiple electrode aggregometry
Adenosine diphosphate-agonist, AUC 22 (0 to 79) 20 (12 to 43) 0.61 65 (30 to 114) 46 (22 to 145) 0.67
Opposite-analysis temperature 21 (4 to 58) 18 (11 to 52) 62 (24 to 140) 61 (40 to 120)
Collagen agonist, AUC 41 (26 to 62) 56 (25 to 117)*** <0.001 64 (42 to 104) 72 (52 to 147)** 0.0039
Opposite-analysis temperature 42 (27 to 94) 49 (27 to 75) 68 (40 to 123) 74 (60 to 122)
Thrombin receptor agonist peptide, AUC 90 (8 to 116) 99 (82 to 151)** 0.006 83 (40 to 153) 98 (91 to 183)** 0.008
Opposite-analysis temperature 86 (7 to 143) 83 (50 to 107) 89 (44 to 154) 102 (83 to 161)
Arachidonic acid-agonist, AUC 11 (2 to 39) 20 (11 to 62)** 0.003 46 (7 to 130) 66 (18 to 163)** 0.0039
Opposite-analysis temperature 14 (3 to 129) 12 (3 to 28)a 50 (9 to 180) 72 (10 to 148)
Sonoclot
Activated clotting time, s 144 (72 to 253) 120 (88 to 191) 0.19 133 (95 to 244) 153 (76 to 213) 0.98
Opposite-analysis temperature 121 (74 to 192) 126 (102 to 226) 120 (79-238)a 166 (81 to 223)
Clotting rate, units/minute 25 (15 to 49) 37 (23 to 47)*** <0.001 28 (18 to 64) 41 (24 to 63) 0.44
Opposite-analysis temperature 33 (18 to 50) 32 (15 to 44)a 39 (22 to 74)a 35 (17 to 46)
Platelet function, units 2.9 (0.4 to 4.4) 3.5 (2.8 to 5.0)*** <0.001 2.9 (0.9 to 4.9) 4.1 (1.8 to 5.2)** 0.0039
Opposite-analysis temperature 4.2 (0.45 to 4.7)b 3.2 (1.3 to 4.2)a 3.9 (1.9 to 5.0) 3.4 (2.7 to 5.1)
Results presented as mean ± SD, median (range (minimum to maximum), or number (%). T1, blood sampling 12 to 24 h after reaching 33°C); T2 blood sampling
16 to 28 h after reaching normothermia. Multiple electrode aggregometry, (Multiplate®) and Sonoclot analyses set on the patient’s body temperature at the
sampling occasion and at Opposite-analysis temperature (that is, 37°C if the patient’s body temperature was 33°C and vice versa). Differences between laboratory
results for T2 versus T1 (P-values) were calculated using two-tailed, paired t-test for means, two-tailed paired Wilcoxon matched pairs signed test for medians and
Fisher’s exact test for categorical variables. **P <0.01. ***P <0.001. aP <0.01 compared to the other analysed temperature. bP <0.001 compared to the other analysed
temperature on the same sampling occasion. VASP, vasodilator-stimulated phosphorylated phosphoprotein; PRI, platelet reactivity index; AUC: area under the curve.
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PT-INR and aPTT were all unchanged between T1 and
T2. Fibrinogen increased from 3.2 ± 0.9 (T1) to 4.9 ± 1.3
(T2), (P =0.002) and CRP increased from 52 ± 38 (T1) to
147 ± 72 (T2) (P <0.001). VASP decreased from 53 ± 28
(T1) to 24 ± 22 (T2), (P <0.001). Multiplate®-analyses, with
the analyses temperature set on the in vivo temperature,
showed no changes in ADP-stimulated platelets. COL,
TRAP and ASPI tests were all increased at T2 compared
to T1 (Table 2 and Figure 2). In the Sonoclot-analyses
ACT was unchanged but both CR and PF was increased
at T2 compared to T1 (Table 2 and Figure 2).
Patients with no platelet inhibition: platelet count,
PT-INR, aPTT, and VASP did not change significantly.
Multiplate®-analyses were performed with the analyses
temperature set on the patient’s body temperature. ADPand TRAP tests were not changed significantly. COL and
ASPI tests increased at T2 compared to T1 (Table 2 and
Figure 2). In the Sonoclot®-analyses ACT and CR
were unchanged but PF was increased in T2 compared to
T1 (Table 2 and Figure 2).
Correlation aspirated gastric secretion - VASP: the
median volume of gastric secretion aspirated in patients
with dual platelet inhibition was 105 (10 to 200) ml during
T1 and 65 (10 to 200) ml during T2 (not significant). The
volume of gastric secretion aspirated during T1 correlated
well with VASP (T1), r =0.81 (P <0.001) (Figure 3). This
correlation was not detected at T2.
Discussion
In this prospective observational study on OHCA patients
treated with MIH we have demonstrated an increase in
T1 T2 T1 T2 T1 T2 T1 T2
T1 T2 T1 T2 T1 T2 T1 T2
T1 T2 T1 T2 T1 T2 T1 T2




















































































Figure 2 Results from blood analyses for individual patients. Multiplate® and Sonoclot instruments set on the in-vivo temperature. PI,
patients with dual platelet inhibition (n =14); nPI, patients with no platelet inhibition (n =9); T1, blood sampling 12 to 24 h after reaching 33°C
body temperature; T2, blood sampling 16 to 28 h after reaching normothermia. Multiple electrode aggregometry, Multiplate®: ADP: adenosine
diphosphate-agonist; COL, collagen-agonist; TRAP, thrombin-agonist; ASPI, arachidonic-acid agonist. Sonoclot analyses: ACT, activated clotting
time; CR, clotting rate; PF, platelet function. AUC, area under curve; **P <0.01; ***P <0.001.
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CR and PF between the stable hypothermic and the stable
normothermic state, indicating increased platelet aggrega-
tion and strengthened clot formation.This observational study did not include a normo-
thermic control group, thus the cause for the increased
platelet aggregability and viscoelastic clot formation be-
tween stable hypothermia (T1) and stable normothermia
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Figure 3 Correlation between aspirated gastric secretion and
vasodilator-stimulated phosphorylated phosphoprotein (VASP).
Patients with dual platelet inhibition (n =14). Gastric secretion T1,
median volume of gastric secretion aspirated from nasogastric tube,
0 to 24 h after reaching 33°C body temperature; VASP T1, 12 to 24 h
after reaching 33°C body temperature; PRI, platelet reactivity index.
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cussed. Hypothermia has been shown to decrease haemo-
stasis measured with viscoelastic methods [11,18,19,28] and
with platelet function testing [16,17,21]. Thus, the lower
temperature at T1 could be responsible for the decreased
values as compared to T2. In addition, post-resuscitation
stress responses after cardiac arrest mimic the immunologic
and coagulation disorders observed in severe sepsis
[41]. Presumably the low-flow state during cardiac ar-
rest, followed by a reperfusion injury after return of
spontaneous circulation is responsible for a SIRS reaction
that may cause an activation of the coagulation system
[36,42]. This can be compared to studies by Adamzik et
al. [33] and Brenner et al. [35] that showed reduced plate-
let aggregation, measured with Multiplate®, in patients
with severe sepsis. In our study CRP and fibrinogen
increased between the sampling occasions (Table 2) in all
patients indicating a significant SIRS with an acute phase
reaction 2 to 3 days after OHCA, although this did not
reach statistical significance in the group without platelet
inhibition.
The effect of ticagrelor depends on intestinal absorp-
tion to the systemic circulation. It is well-known that
hypothermia, opioids and acute critical illness reduce
gastrointestinal motility [43]. In the present study 50%
of the patients with dual platelet inhibition did not reach
the target VASP PRI <50% at the first sampling occasion
(T1), thus placing them at risk for thromboembolic
events. This is in agreement with previous findings of
impaired bioavailability of clopidogrel in critically ill pa-
tients [44] and comparable with the results from Bjelland
et al. [31] and Ibrahim et al. [32], which demonstrated high
rates of non-responders in clopidogrel-treated patients(100% and 83%, respectively) as well as in ticagrelor-
treated patients (61%) [45] in MIH after cardiac arrest. In
the present study we also demonstrated significant cor-
relation between gastric emptying and VASP during hy-
pothermia (Figure 3), indicating that gastric emptying is
responsible for the limited ticagrelor effect observed at T1.
These findings underline the importance of stimulating
motility of the gastro-intestinal tract as soon as possible in
the cardiac arrest patient who is dependent on absorption
of oral P2Y12 inhibitors to limit the risk of stent throm-
bosis. This is also demonstrated in a recent observational
study by Joffe et al. [46], including patients with acute
myocardial infarction treated with coronary stents. In the
study by Joffe et al. cardiac arrest patients did not receive
P2Y12 inhibitors and had a much higher incidence of stent
thrombosis (10.9%) than patients in the control group
(2.0%), who were treated with P2Y12 inhibitors but had not
had previous cardiac arrests.
VASP analysis is specifically designed to monitor only
the P2Y12 platelet inhibitory effect on platelets [38] and
as expected, only patients on P2Y12 platelet inhibitory
medication actually exhibited VASP changes. Multiplate®
and Sonoclot tests on the other hand, are not as specific
as VASP analysis and are sensitive to many pro- and anti-
haemostatic variables [24,25,33,35,47], not detectable with
VASP. Furthermore, Multiplate®-assays (except ADPassay)
and Sonoclot assays cannot detect moderate P2Y12inhibi-
tion [30]. These characteristics of the different analyses
explain why Multiplate®-assays, COL, TRAP, ASPI and
Sonoclot assays, CR and PF, in our study show strength-
ened platelet function and coagulation over time, and on
the other hand, P2Y12-sensitive VASP analysis show weak-
ened platelet function in ticagrelor treated patients.
We performed all Multiplate® and Sonoclot analyses
with the instruments set both at the patient’s actual body
temperature (the in vivo temperature) and at the opposite
temperature, that is, 33°C or 37°C. This was not per-
formed to determine whether the rise in body temperature
or the SIRS is responsible for the increased values in nor-
mothermia, but rather to identify how the temperature of
the instrument affects the results. We found that ASPItest
in the Multiplate® analyses and multiple assays in the
Sonoclot analyses indicated weaker values when normo-
thermic samples were cooled and stronger values when
hypothermic samples were warmed (Table 2). This is in
agreement with results from Shimokawa et al. [11] that
showed the importance of performing hemostatic mea-
surements with the Sonoclot and thromboelastography at
the actual in vivo (hypothermic) temperature and not only
at the traditional 37°C setting. The PF platelet parameter
used in the present study better reflects clot contraction
than the parameters used by Shimokawa [40].
Other limitations of the present study include that
platelet function assay was done under minimal shear, so
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haematocrit and von Willebrand Factor, could not be
assessed [48]. Furthermore, this study did not explore
the causes for the increased platelet aggregability and
the viscoelastic clot formation. We welcome a random-
ized controlled trial to explore whether hypothermia, the
SIRS reaction, an unknown factor or a combination of
factors are responsible for the observed changes.
Conclusions
We have demonstrated increased platelet aggregation and
strengthened clot formation over time in out-of-hospital
cardiac arrest patients treated with hypothermia. In pa-
tients on oral dual platelet inhibition, the effect of ticagre-
lor was delayed, probably due to slow gastric emptying.
Key messages
 Platelet aggregation and clot formation
demonstrated with Multiplate® and Sonoclot are
strengthened over time in out-of-hospital cardiac
arrest patients treated with hypothermia
 Fifty percent of the patients on oral ticagrelor did
not reach the target VASP PRI <50% at the first
sampling occasion 12 to 24 hours after reaching
hypothermia, thus placing them at risk for
thromboembolic events
 The effect of ticagrelor was delayed in survivors of
cardiac arrest, probably due to slow gastric emptying
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